anti-inflammatoty and immuno-therapy - versus placebo - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.62 [0.43, 0.90]< 10%2 studies (2/-)99.4 %some concernnot evaluable moderatecrucial-
deaths 0.61 [0.46, 0.81]< 10%6 studies (6/-)100.0 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.70 [0.40, 1.21]< 10%1 study (1/-)89.9 %NAnot evaluable crucial-
clinical deterioration 0.40 [0.29, 0.55]< 113%2 studies (2/-)100.0 %lownot evaluable highimportant-
clinical improvement 1.39 [0.76, 2.54]> 10%1 study (1/-)85.8 %NAnot evaluable important-
death or ventilation 0.65 [0.50, 0.86]< 10%2 studies (2/-)99.9 %some concernnot evaluable moderateimportant-
hospital discharge 1.48 [1.05, 2.09]> 10%1 study (1/-)98.6 %NAnot evaluable important-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %NAnot evaluable important-
mechanical ventilation 0.47 [0.03, 7.48]< 10%1 study (1/-)70.4 %NAnot evaluable important-
viral clearance 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %NAnot evaluable important-
viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %NAnot evaluable important-
ICU admission 0.33 [0.07, 1.58]< 10%1 study (1/-)91.7 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.75 [0.47, 1.19]< 10%2 studies (2/-)89.0 %some concernnot evaluable moderateimportant-
adverse events 1.33 [0.63, 2.78]< 10%1 study (1/-)22.7 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.